Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ: Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride
In March 2026, Structure reported 44-week topline data from the ACCESS II Phase 2 study, showing placebo-adjusted weight loss of up to 16.3%, which the company described as the highest efficacy demonstrated among oral GLP-1 receptor agonists at that time point
Critics argue that weakening these rules would leave tens of millions unprotected particularly residents of states without their own PFAS limits
According to MHRA product information, constipation occurs in approximately 20% of patients taking higher doses for weight management, while rates are lower with diabetes doses
The study, which ended prematurely due to a higher mortality rate in the intensive treatment group, failed to report significant reduction in major cardiovascular events, giving a notion that intensive therapy was associated with significant harm in high risk patients [6]